The progression of Parkinson's disease often requires a change of therapy. An expert explains when this should be done and ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug ...

Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...